Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
- PMID: 33958800
- PMCID: PMC8101331
- DOI: 10.1038/s41591-021-01372-z
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Erratum for
-
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.Nat Med. 2021 Feb;27(2):279-288. doi: 10.1038/s41591-020-01179-4. Epub 2020 Dec 17. Nat Med. 2021. PMID: 33335322 Clinical Trial.
Similar articles
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20. Lancet. 2020. PMID: 32702298 Free PMC article. Clinical Trial.
-
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.Nat Med. 2021 Feb;27(2):279-288. doi: 10.1038/s41591-020-01179-4. Epub 2020 Dec 17. Nat Med. 2021. PMID: 33335322 Clinical Trial.
-
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.Lancet. 2021 Mar 6;397(10277):881-891. doi: 10.1016/S0140-6736(21)00432-3. Epub 2021 Feb 19. Lancet. 2021. PMID: 33617777 Free PMC article.
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.Lancet HIV. 2021 Sep;8(9):e568-e580. doi: 10.1016/S2352-3018(21)00157-0. Epub 2021 Aug 17. Lancet HIV. 2021. PMID: 34416193 Free PMC article. Clinical Trial.
-
MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.J Neurol. 2022 Oct;269(10):5198-5212. doi: 10.1007/s00415-022-11194-9. Epub 2022 Jun 23. J Neurol. 2022. PMID: 35737110 Free PMC article. Review.
Cited by
-
Vaccinal antibodies: Fc antibody engineering to improve the antiviral antibody response and induce vaccine-like effects.Hum Vaccin Immunother. 2021 Dec 2;17(12):5532-5545. doi: 10.1080/21645515.2021.1985891. Epub 2021 Nov 29. Hum Vaccin Immunother. 2021. PMID: 34844516 Free PMC article. Review.
-
Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine.Cell Rep Med. 2022 Jul 19;3(7):100685. doi: 10.1016/j.xcrm.2022.100685. Cell Rep Med. 2022. PMID: 35858586 Free PMC article.
-
Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm's COVID-19 Vaccines.Front Immunol. 2022 Jun 21;13:917905. doi: 10.3389/fimmu.2022.917905. eCollection 2022. Front Immunol. 2022. PMID: 35799790 Free PMC article.
-
Harnessing T-Cells for Enhanced Vaccine Development against Viral Infections.Vaccines (Basel). 2024 Apr 29;12(5):478. doi: 10.3390/vaccines12050478. Vaccines (Basel). 2024. PMID: 38793729 Free PMC article. Review.
-
The clinical correlates of vaccine-induced immune thrombotic thrombocytopenia after immunisation with adenovirus vector-based SARS-CoV-2 vaccines.Immunother Adv. 2021 Aug 17;1(1):ltab019. doi: 10.1093/immadv/ltab019. eCollection 2021 Jan. Immunother Adv. 2021. PMID: 34557868 Free PMC article. Review.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous